Laborie Medical Technologies (“LABORIE”), a leading global developer and manufacturer of medical diagnostics and devices in the pelvic health and gastroenterology markets, is pleased to announce Michael Frazzette as new President and CEO. Mike brings over three decades of broad Medical Technology leadership experience to his role. “Clinicians know Laborie Medical Technologies as a global leader and innovative partner working to help improve patient outcomes. I am honored to be joining such a high performing and customer focused team, and I look forward to building upon our strengths to create even more value for all of our stakeholders,” said Mike. LABORIE Chairman, Bo Jesper Hansen, MD stated, “Speaking on behalf of the Board of Directors, we are thrilled to have Mike join the LABORIE team as CEO, and we are excited about the long-term prospects of Laborie under his leadership.”
Prior to joining LABORIE, Mike served for 11 years at Smith & Nephew plc (LON: SN), a $4.8 billion Medical Technology company. He joined Smith & Nephew as President of its Endoscopy Global Business Unit, then served as President of its Advanced Surgical Devices Division, comprised of the Orthopedic, Trauma, and Endoscopy businesses. Most recently, he served as Chief Commercial Officer for Smith & Nephew, leading the global operations of the entire company. Mike successfully led the business in both profitable organic growth, as well as strategic mergers and acquisitions. Mike’s previous experience includes executive leadership roles at Kendall Healthcare, Tyco Healthcare, and CEO of MicroGroup, a privately-held medical manufacturing business in Massachusetts.
LABORIE is a leading global developer, manufacturer and marketer of innovative medical technology and consumables used for the diagnosis and treatment of pelvic floor disorders in the Urology, Gynecology, and Colorectal fields.
LABORIE is owned by Patricia Industries – a part of Investor AB – and is a long-term owner that invests in companies and works to develop each company to its full potential.